company background image
EDSA logo

Edesa Biotech NasdaqCM:EDSA Stock Report

Last Price

US$4.99

Market Cap

US$15.8m

7D

-7.1%

1Y

-49.1%

Updated

24 Feb, 2024

Data

Company Financials +

Edesa Biotech, Inc.

NasdaqCM:EDSA Stock Report

Market Cap: US$15.8m

EDSA Stock Overview

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.

EDSA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Edesa Biotech, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Edesa Biotech
Historical stock prices
Current Share PriceUS$4.99
52 Week HighUS$10.36
52 Week LowUS$2.46
Beta0.93
1 Month Change6.17%
3 Month Change53.54%
1 Year Change-49.08%
3 Year Change-87.09%
5 Year Changen/a
Change since IPO-86.29%

Recent News & Updates

Recent updates

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Aug 04
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Mar 10
We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Sep 30

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Sep 23
Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa says mid-stage trial for anti-allergic cream reached full enrollment

Sep 07

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Aug 12

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

May 16
Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Apr 18

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Dec 08
Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Sep 22

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Aug 27
Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Jun 18

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Feb 19
Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Edesa Biotech receives C$14M for COVID-19 study

Feb 02

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Dec 08
Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa Biotech EPS misses by $0.04, beats on revenue

Dec 07

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Nov 03

Shareholder Returns

EDSAUS BiotechsUS Market
7D-7.1%1.5%1.3%
1Y-49.1%10.5%25.6%

Return vs Industry: EDSA underperformed the US Biotechs industry which returned 8.1% over the past year.

Return vs Market: EDSA underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is EDSA's price volatile compared to industry and market?
EDSA volatility
EDSA Average Weekly Movement12.1%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: EDSA's share price has been volatile over the past 3 months.

Volatility Over Time: EDSA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201516Par Nijhawanhttps://www.edesabiotech.com

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.

Edesa Biotech, Inc. Fundamentals Summary

How do Edesa Biotech's earnings and revenue compare to its market cap?
EDSA fundamental statistics
Market capUS$15.83m
Earnings (TTM)-US$7.72m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EDSA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$7.72m
Earnings-US$7.72m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.43
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did EDSA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.